Sipuleucel-T, the first therapeutic vaccine for prostate cancer, is safe for use in outpatients, according to a new report.
Designed to stimulate an immune response against prostate cancer, sipuleucel-T (Provenge) must be prepared specifically for each patient using autologous dendritic cells. It was approved by the U.S. Food and Drug Administration in April 2010 for men with asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer
Designed to stimulate an immune response against prostate cancer, sipuleucel-T (Provenge) must be prepared specifically for each patient using autologous dendritic cells. It was approved by the U.S. Food and Drug Administration in April 2010 for men with asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.